<DOC>
	<DOC>NCT01543867</DOC>
	<brief_summary>This study is conducted in Europe. The aim of this study is to evaluate safety during the long-term use of somatropin (NorditropinÂ®) in children as well as efficacy on change in height. A subgroup of children small for their gestational age is included.</brief_summary>
	<brief_title>Safety and Efficacy of Long-term Somatropin Treatment in Children</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Dwarfism, Pituitary</mesh_term>
	<mesh_term>Turner Syndrome</mesh_term>
	<mesh_term>Gonadal Dysgenesis</mesh_term>
	<mesh_term>Primary Ovarian Insufficiency</mesh_term>
	<mesh_term>Dwarfism</mesh_term>
	<mesh_term>Growth Disorders</mesh_term>
	<criteria>In need of somatropin or current user</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>